<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Asahi Kasei Corporation — News on 6ix</title>
<link>https://6ix.com/company/asahi-kasei-corporation</link>
<description>Latest news and press releases for Asahi Kasei Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/asahi-kasei-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6199cbeedb30cb6fbf160.webp</url>
<title>Asahi Kasei Corporation</title>
<link>https://6ix.com/company/asahi-kasei-corporation</link>
</image>
<item>
<title>Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-completes-acquisition-of-aicuris-to-advance-its-global-pharmaceutical-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-completes-acquisition-of-aicuris-to-advance-its-global-pharmaceutical-strategy</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>TOKYO, April 20, 2026--Asahi Kasei has announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris).</description>
</item>
<item>
<title>Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-announces-initiation-of-phase-i-clinical-trial-for-novel-peptide-candidate-targeting-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-announces-initiation-of-phase-i-clinical-trial-for-novel-peptide-candidate-targeting-autoimmune-diseases</guid>
<pubDate>Mon, 20 Apr 2026 10:30:00 GMT</pubDate>
<description>TOKYO, April 20, 2026--Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound.</description>
</item>
<item>
<title>Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/calliditas-therapeutics-ab-to-present-exploratory-biomarker-and-post-hoc-nefigard-analyses-at-the-world-congress-of-nephrology</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/calliditas-therapeutics-ab-to-present-exploratory-biomarker-and-post-hoc-nefigard-analyses-at-the-world-congress-of-nephrology</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>Calliditas Therapeutics AB, an Asahi Kasei company, announced today that new data from the Phase 3 NefIgArd study in patients with primary immunoglobulin A nephropathy (IgAN) will be presented at the 2026 World Congress of Nephrology (WCN), taking place from March 28 to 31 in Yokohama, Japan.</description>
</item>
<item>
<title>Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/chevron-technology-ventures-asahi-kasei-invest-in-heavy-industry-robotics-company-kewazo</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/chevron-technology-ventures-asahi-kasei-invest-in-heavy-industry-robotics-company-kewazo</guid>
<pubDate>Thu, 19 Mar 2026 15:15:00 GMT</pubDate>
<description>MUNICH & HOUSTON, March 19, 2026--KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, Benson Capital, Mana Ventures, Gaingels, and Atlas Ventures, alongside lead investor Schooner Capital and existing investors True Ventures and Cybernetix Ventures. Total funding now reaches $35M.</description>
</item>
<item>
<title>Tanahashi Prize Recognizes the Robust Long-Term Operation of the 10MW Alkaline-Water Electrolysis System by Asahi Kasei</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/tanahashi-prize-recognizes-the-robust-long-term-operation-of-the-10mw-alkaline-water-electrolysis-system-by-asahi-kasei</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/tanahashi-prize-recognizes-the-robust-long-term-operation-of-the-10mw-alkaline-water-electrolysis-system-by-asahi-kasei</guid>
<pubDate>Thu, 19 Mar 2026 12:30:00 GMT</pubDate>
<description>TOKYO, March 19, 2026--Six engineers from Asahi Kasei were awarded the Tanahashi Prize for their contributions to the development of an alkaline-water electrolysis system.</description>
</item>
<item>
<title>Asahi Kasei, Nippon Steel, and Nippon Steel Trading Recycle Chlor-Alkali Electrolysis Cell Production Scrap Back into High-Quality Pure Titanium</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-nippon-steel-and-nippon-steel-trading-recycle-chlor-alkali-electrolysis-cell-production-scrap-back-into-high-quality-pure-titanium</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-nippon-steel-and-nippon-steel-trading-recycle-chlor-alkali-electrolysis-cell-production-scrap-back-into-high-quality-pure-titanium</guid>
<pubDate>Wed, 18 Mar 2026 12:30:00 GMT</pubDate>
<description>TOKYO, March 18, 2026--Asahi Kasei, Nippon Steel, and Nippon Steel Trading have launched a recycling initiative to convert titanium scrap into a raw material for titanium.</description>
</item>
<item>
<title>Asahi Kasei Begins Installation of Containerized Alkaline-Water Electrolyzer at Finland’s First Commercial Hydrogen Refueling Station</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-begins-installation-of-containerized-alkaline-water-electrolyzer-at-finlands-first-commercial-hydrogen-refueling-station-1</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-begins-installation-of-containerized-alkaline-water-electrolyzer-at-finlands-first-commercial-hydrogen-refueling-station-1</guid>
<pubDate>Thu, 12 Mar 2026 12:30:00 GMT</pubDate>
<description>TOKYO, March 12, 2026--Asahi Kasei has started the installation of an Aqualyzer™-C3 at Finland’s first commercial hydrogen refueling station in Jyväskylä.</description>
</item>
<item>
<title>Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-strengthens-global-pharmaceutical-platform-with-the-acquisition-of-aicuris</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-strengthens-global-pharmaceutical-platform-with-the-acquisition-of-aicuris</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>CHELMSFORD, Mass. & TOKYO, February 26, 2026--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG.</description>
</item>
<item>
<title>Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-to-acquire-aicuris-to-accelerate-growth-in-severe-infectious-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-to-acquire-aicuris-to-accelerate-growth-in-severe-infectious-diseases</guid>
<pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
<description>Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U.S. subsidiary Veloxis Pharmaceuticals, Inc., will acquire all shares of Aicuris for a total of €780 million (~$920 million*). The acquisition will enable Asahi Kasei to strategically expand its portfolio of therapies designed to treat severe viral infections, addressing critical infectious complicat</description>
</item>
<item>
<title>Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-pharma-strengthens-preclinical-pipeline-through-exclusive-global-license-agreement-with-alchemedicine-for-novel-lead-compounds</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-pharma-strengthens-preclinical-pipeline-through-exclusive-global-license-agreement-with-alchemedicine-for-novel-lead-compounds</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>TOKYO, February 25, 2026--Asahi Kasei Pharma announced an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine.</description>
</item>
<item>
<title>IEEE Recognizes Asahi Kasei Microdevices’ Commercialization of Thin-Film Hall Elements as an IEEE Milestone</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/ieee-recognizes-asahi-kasei-microdevices-commercialization-of-thin-film-hall-elements-as-an-ieee-milestone</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/ieee-recognizes-asahi-kasei-microdevices-commercialization-of-thin-film-hall-elements-as-an-ieee-milestone</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>TOKYO, February 19, 2026--Asahi Kasei Microdevices Corporation's commercialization of thin-film Hall elements has been recognized as an IEEE Milestone.</description>
</item>
<item>
<title>Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-pharma-and-alchemedicine-advance-a-novel-therapeutic-candidate-into-phase-i-study-for-the-treatment-of-refractory-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-pharma-and-alchemedicine-advance-a-novel-therapeutic-candidate-into-phase-i-study-for-the-treatment-of-refractory-diseases</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>TOKYO, February 18, 2026--Asahi Kasei Pharma in collaboration with Alchemedicine has announced that AK1960 has advanced to a Phase I clinical study.</description>
</item>
<item>
<title>ZOLL Medical Appoints Eric Knudsen as New CEO</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/zoll-medical-appoints-eric-knudsen-as-new-ceo</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/zoll-medical-appoints-eric-knudsen-as-new-ceo</guid>
<pubDate>Wed, 04 Feb 2026 14:30:00 GMT</pubDate>
<description>CHELMSFORD, Mass., February 04, 2026--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has appointed Eric Knudsen as its new Chief Executive Officer, effective April 1. Knudsen will succeed Jon Rennert, who served as ZOLL’s CEO for the past 10 years and will assume a new role as Executive Chairman of ZOLL’s Board of Directors.</description>
</item>
<item>
<title>Asahi Kasei Develops PFAS-Free PA66 Offering Low-Friction and High-Load Performance</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-develops-pfas-free-pa66-offering-low-friction-and-high-load-performance</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-develops-pfas-free-pa66-offering-low-friction-and-high-load-performance</guid>
<pubDate>Thu, 29 Jan 2026 13:30:00 GMT</pubDate>
<description>DUESSELDORF, Germany, January 29, 2026--Asahi Kasei announced the development of a new PFAS-free polyamide (PA) engineered specifically for demanding low-friction applications.</description>
</item>
<item>
<title>Bionique Testing Laboratories Appoints Dr. Andy Bailey, Strengthening Global Biosafety Testing</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/bionique-testing-laboratories-appoints-dr-andy-bailey-strengthening-global-biosafety-testing</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/bionique-testing-laboratories-appoints-dr-andy-bailey-strengthening-global-biosafety-testing</guid>
<pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
<description>Bionique Testing Laboratories (Bionique), a subsidiary of Asahi Kasei and a globally recognized specialist in mycoplasma and biosafety testing services for the life science industry, today announced the appointment of Andy Bailey, PhD, as President and Chief Executive Officer, effective April 1, 2026.</description>
</item>
<item>
<title>Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical enter basic agreement to promote decarbonization of ethylene production in western Japan</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-mitsui-chemicals-and-mitsubishi-chemical-enter-basic-agreement-to-promote-decarbonization-of-ethylene-production-in-western-japan</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-mitsui-chemicals-and-mitsubishi-chemical-enter-basic-agreement-to-promote-decarbonization-of-ethylene-production-in-western-japan</guid>
<pubDate>Tue, 27 Jan 2026 13:30:00 GMT</pubDate>
<description>TOKYO, January 27, 2026--Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical promote decarbonization and optimize production capacity for ethylene manufacturing facilities.</description>
</item>
<item>
<title>ZOLL Strengthens Growth Trajectory for Asahi Kasei’s Healthcare Sector with U.S. Launch of the Next-Generation LifeVest® WCD and Rollout of the Most Comfortable LifeVest Garment Ever, Reinforcing Position as Leader in WCD Category</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/zoll-strengthens-growth-trajectory-for-asahi-kaseis-healthcare-sector-with-us-launch-of-the-next-generation-lifevestr-wcd-and-rollout-of-the-most-comfortable-lifevest-garment-ever-reinforcing-position-as-leader-in-wcd-category</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/zoll-strengthens-growth-trajectory-for-asahi-kaseis-healthcare-sector-with-us-launch-of-the-next-generation-lifevestr-wcd-and-rollout-of-the-most-comfortable-lifevest-garment-ever-reinforcing-position-as-leader-in-wcd-category</guid>
<pubDate>Thu, 08 Jan 2026 16:05:00 GMT</pubDate>
<description>CHELMSFORD, Mass. & TOKYO, January 08, 2026--Asahi Kasei announced that ZOLL® Medical has launched the next-generation LifeVest® wearable cardioverter defibrillator (WCD) in the U.S.</description>
</item>
<item>
<title>Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-pharma-to-relocate-global-randd-hub-to-shonan-ipark</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-pharma-to-relocate-global-randd-hub-to-shonan-ipark</guid>
<pubDate>Mon, 22 Dec 2025 13:30:00 GMT</pubDate>
<description>TOKYO, December 22, 2025--Asahi Kasei Pharma Corporation has announced plans to relocate its R&D hub from Izunokuni City, Shizuoka Prefecture to Shonan Health Innovation Park.</description>
</item>
<item>
<title>Asahi Kasei Microdevices and Aizip Deliver Transformative AI-Enhanced Sensing Solutions</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-microdevices-and-aizip-deliver-transformative-ai-enhanced-sensing-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-microdevices-and-aizip-deliver-transformative-ai-enhanced-sensing-solutions</guid>
<pubDate>Tue, 16 Dec 2025 13:30:00 GMT</pubDate>
<description>TOKYO, December 16, 2025--Asahi Kasei Microdevices (AKM) and Aizip have partnered to showcase two innovations in AI-enhanced sensing.</description>
</item>
<item>
<title>Asahi Kasei Receives 2025 TSMC Excellent Performance Award in Recognition of Its PIMEL™ Photosensitive Dielectric for Advanced Packaging Material</title>
<link>https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-receives-2025-tsmc-excellent-performance-award-in-recognition-of-its-pimeltm-photosensitive-dielectric-for-advanced-packaging-material</link>
<guid isPermaLink="true">https://6ix.com/company/asahi-kasei-corporation/news/asahi-kasei-receives-2025-tsmc-excellent-performance-award-in-recognition-of-its-pimeltm-photosensitive-dielectric-for-advanced-packaging-material</guid>
<pubDate>Fri, 12 Dec 2025 13:30:00 GMT</pubDate>
<description>TOKYO, December 12, 2025--Asahi Kasei received a 2025 TSMC Excellent Performance Award for "Excellent Technology Development and Production Support."</description>
</item>
</channel>
</rss>